イオフルパン (123I) (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "イオフルパン (123I)" in Japanese language version.

refsWebsite

Global rank Japanese rank

4^th place

24^th place

2^nd place

6^th place

1^st place

2,755^th place

9,877^th place

68^th place

425^th place

6,690^th place

394^th place

432^nd place

1,191^st place

doi.org

“EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2”. European Journal of Nuclear Medicine and Molecular Imaging 37 (2): 443–50. (February 2010). doi:10.1007/s00259-009-1267-x. PMID 19838702.
“SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0”. Journal of Nuclear Medicine 53 (1): 154–63. (January 2012). doi:10.2967/jnumed.111.100784. PMID 22159160.

“DaTSCAN Summary of Product Characteristics”. European Medicines Agency. GE Healthcare (25 July 2019). 2021年5月9日閲覧。

“EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2”. European Journal of Nuclear Medicine and Molecular Imaging 37 (2): 443–50. (February 2010). doi:10.1007/s00259-009-1267-x. PMID 19838702.
“SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0”. Journal of Nuclear Medicine 53 (1): 154–63. (January 2012). doi:10.2967/jnumed.111.100784. PMID 22159160.

“Datscan- ioflupane i-123 injection, solution”. DailyMed (31 March 2020). 23 April 2021閲覧。

“Removal of [¹²³IIoflupane From Schedule II of the Controlled Substances Act]”. DEA Diversion Control Division. 13 May 2017時点のオリジナルよりアーカイブ。2016年2月9日閲覧。

“Removal of [¹²³IIoflupane From Schedule II of the Controlled Substances Act]”. DEA Diversion Control Division. 13 May 2017時点のオリジナルよりアーカイブ。2016年2月9日閲覧。